INTRODUCTION
Transforming growth factor-β (TGF-β) is a ubiquitously expressed cytokine that controls a plethora of cellular responses from cell proliferation, differentiation and apoptosis to embryonic development in metazoan. [1] [2] [3] Numerous studies have established a model for the transduction of signals from TGF-β receptors to the nucleus in mammalian cells. In the canonical TGF-β signaling pathway, Smad proteins are the central mediators and are classified into three groups, including receptor-associated Smads (R-Smads), common Smad (Smad4) and inhibitory Smads (I-Smads). 4 Upon TGF-β stimulation, heteromeric receptors phosphorylate R-Smads on their SXS motifs. 5 Subsequently, R-Smads form a heter-oligomeric complex with Smad4 and then translocate into the nucleus, where they cooperate with transcriptional co-activators and co-repressors to regulate responses of target genes. 6, 7 Smad proteins share two highly conserved domains at their N and C termini, known as the Mad homology 1 (MH1) and Mad homology 2 (MH2) domains, respectively. The MH1 domain is responsible for the binding with Smad-binding element (SBE), whereas the MH2 domain contributes to the Smad transcriptional activity. 8, 9 In fact, Smad transcriptional complexes target specific genes by recruitment of transcription co-factors to the target promoters. 9 The most well-characterized Smad co-activator is the general co-transcriptional factor CBP/p300, which facilitates transcription by decreasing chromosome condensation through its intrinsic histone acetyltransferase activity and by increasing the accessibility of transcription factors to the basal transcription machinery. 10 By directly binding with Smads, CBP/p300 positively regulates Smad-mediated transcriptional activation in the TGF-β signaling pathway. 11 Increasing numbers of transcription (co) factors, including P/CAF, SIP1, TGIF and SMIF, have been identified, which further help to understand the context-dependent regulation of TGF-β transcriptional responses. 8, [12] [13] [14] [15] Bromodomain-containing protein 7 (BRD7) is an evolutionarily conserved protein that contains a single bromodomain. Previous studies showed that BRD7 exerts multiple cellular functions through regulation of cell cycle progression. BRD7 affects PI3K signaling, mediates chromatin remodeling and regulates p53-dependent replicative senescence. [16] [17] [18] [19] [20] As a component of chromatin remodeling SWI/SNF complexes, BRD7 function as a transcriptional co-activator or co-repressor. Indeed, BRD7 serves as a transcription co-activator for tumor suppressors BRCA1 and p53 to regulate target gene transcription. [18] [19] [20] Together with the previous report that a low level of BRD7 protein is found in various tumor types, [21] [22] [23] [24] BRD7 could be an important tumor suppressor that deserves more attention.
Here we demonstrate a novel function of BRD7 in TGF-β signaling. BRD7 interacts with the Smad tumor suppressor complex, and enhances both DNA-binding ability and transcriptional activity of Smads. BRD7 functions in growth inhibition and tumor suppression partly as a transcriptional co-activator of Smads.
RESULTS

BRD7 interacts with Smad3 and Smad4 under physiological conditions
In search for Smad regulatory proteins, we identified BRD7 as a Smad-interacting protein in protein interaction screens (unpublished observations). To validate this interaction with physiological significance, we examined the ability of BRD7 protein to bind to Smads in mammalian cells. First, HEK293T cells were co-transfected with HA-tagged BRD7 and FLAG-tagged Smads (Smad1-4), and co-immunoprecipitation (co-IP) of cell lysates was carried out and followed by immunoblotting. Results indicate that BRD7 strongly interacted with Smad1 and Smad3, and weakly with Smad2 and Smad4 in HEK293T cells ( Figure 1a ). Similar results were obtained by using in vitro protein binding assays ( Figure 1b ). We were further interested in the Smad-BRD7 interaction under physiological conditions by performing co-IP experiments with both proteins at endogenous levels. In the absence of good BRD7 antibodies, we first established A549 cells stably expressing HA-BRD7. Co-IP analysis revealed that TGF-β induced the association between BRD7 and Smad3 (Figure 1c, lane 4) . Consistent with the fact that TGF-β induces the R-Smads-Smad4 protein complex formation, BRD7 also interacted with Smad4 at the endogenous levels, and this interaction was further enhanced by TGF-β treatment (Figure 1d , lane 3). Furthermore, we carried out sequential co-IP to explore if BRD7 forms a ternary complex with both Smad3 and Smad4. The result showed that BRD7 could associate with activated Smad protein complex upon TGF-β treatment (Figure 1e ), implicating a potential role of BRD7 in the TGF-β signaling pathway. Interestingly, Smad3 depletion has no obvious effect on the interaction between BRD7 and Smad4 (Figure 1f, lane 3) , indicating that the interactions between BRD7 and Smad3 or Smad4 are independent.
The N terminus of BRD7 contains a Smad-binding domain Next, we generated a series of deletion mutants to map the regions within Smad3/4 and BRD7 that mediate their interactions. We first determined the domains of Smads for BRD7 interaction. Smad proteins contain the highly conserved MH1 and MH2 domains, linked with the less conserved linker region ( Figure 1g ). Results of co-IP analysis demonstrate that the MH1 and MH2 domains of Smad3 sufficed to confer BRD7 binding as deletion of the linker region had no effects on BRD7 binding (Figure 1h ). In accordance, Smad3 with deletion of either the MH1 domain or the MH2 domain failed to interact with BRD7 ( Figure 1h ). Similar results were obtained for Smad4 binding to BRD7 ( Supplementary  Figures 1A and B ).
BRD7 is an under-characterized protein with 651 amino acids. It has a conserved bromodomain (aa 135-232) and an uncharacterized yet conserved domain (aa 286-534) ( Figure 1i ). Deletion analysis of individual regions of BRD7 demonstrates that the very N terminus before bromodomain on BRD7 (BRD7N Figure 1E ). Glutathione S-transferase (GST) pull-down assays confirmed the direct interaction of BRD7N with Smad3 ( Figure 1 ) or Smad4 (Supplementary Figure 1F ).
BRD7 potentiates TGF-β-induced transcriptional responses
In order to reveal the function of BRD7 in TGF-β signaling pathway, we determined the effects of BRD7 on TGF-β-induced Smad-dependent transcriptional responses. First, we evaluated the effect of overexpressed BRD7 on TGF-β responses by using Smad-binding element (SBE)-luc, a synthetic TGF-β-responsive reporter gene dependent on Smad activation, in both HaCaT and A549 cells. Overexpressed BRD7 caused a significant increase in TGF-β-induced transcriptional activation from SBE-luc reporter in both HaCaT (Figure 2a ) and A549 cells ( Supplementary Figure 2A ). Since TGF-β upregulates transcription of the extracellular matrix component plasminogen activator inhibitor-1 (PAI-1), we also examined the effect of BRD7 on PAI-1-luc reporter expression. Similarly to SBE-luc expression, PAI-luc expression was profoundly increased by BRD7 (Figure 2b ; Supplementary Figure 2B ).
We further investigated whether BRD7 enhances TGF-β-induced expression of endogenous genes. As reported, TGF-β inhibits epithelial cell growth partially via induction of the cell cycle inhibitor p21 (WAF/Cip1). 25 Consistent with the increased TGF-βinduced reporter transcriptional activation (Figures 2a and b ), increased expression of BRD7 significantly enhanced the TGF-βinduced expression of endogenous p21, as demonstrated by quantitative real-time PCR (qRT-PCR) (Figures 2c and d) .
We then took a loss-of-expression approach to address the effect of BRD7 on TGF-β transcriptional responses. Approximatelỹ 90% knockdown efficiencies of BRD7 could be achieved at both mRNA and protein levels ( Figure 3e ). When endogenous BRD7 was knocked down in A549 cells, we noted a dramatic reduction of TGF-β-induced transcriptional activation of the SBE-luc and PAI-1-luc reporter genes ( Supplementary Figures 2C  and D) . Importantly, depletion of BRD7 decreased the TGF-βinduced expression of p21 mRNA in both HaCaT and A549 cells (Figures 2f and g) . In accordance, knockdown of BRD7 reduced the levels of p21 proteins in response to TGF-β (Figures 2h and i).
BRD7 bridges the Smad-chromatin interaction via its bromodomain
To elucidate the mechanism of how BRD7 enhances TGF-βinduced cell signaling, we examined the possibility that BRD7 is directly involved in TGF-β-induced transcriptional regulation. Smads, as transcription factors, possess both DNA-binding and transactivation properties. Since both Smad3 and Smad4 can directly bind to DNA, we first tested whether BRD7 could promote Smad3/Smad4 DNA-binding ability by using SBE oligo pull-down assay. The DNA pull-down assay revealed that BRD7 dramatically increased binding of Smad3/Smad4 to the SBE oligonucleotide ( Figure 3a ). To further address the effect of BRD7 on Smad DNA binding in the chromatin environment, we carried out chromatin immunoprecipitation (ChIP) assays on the p21 promoter in A549 cells. The result demonstrated that BRD7 increased Smad4 binding to the p21 promoter in the presence of TGF-β ( Figure 3b ).
BRD7 contains a highly conserved bromodomain, which is present in many chromatin-associated transcription factors and some nuclear histone acetyltransferases. 16 Considering the fact that BRD7 interacts with acetylated histone H3 through its bromodomain to exhibit transcriptional regulation activity, 26 we examined whether BRD7 stabilizes the Smad4-DNA complex through its association with acetylated histone on chromatin. Notably, BRD7 bound to acH3K9 more strongly upon TGF-β treatment ( Figure 3c BRD7 cooperates with p300 to enhance Smad4 transcriptional activity The MH2 domain of Smads displays transcriptional activity when tethered to DNA via a heterogonous GAL4 DNA-binding domain, 27 partly through the function of coactivators CBP/p300. 11 To examine if BRD7 enhances Smad4 transcriptional activity, we performed a heterologous reporter gene assay using the GAL4 fusion system. Results demonstrate that BRD7 enhanced the transcription activity of Smad4C (Smad4MH2) (Figure 4a ). Since CBP/p300 binds to Smads 11 and BRD7, 19 we reason that BRD7 and CBP/p300 cooperate to mediate Smad-dependent transcription. There was indeed an interaction between BRD7 and CBP/p300, and furthermore, TGF-β significantly increased the BRD7-p300 association ( Figure 4b ). We further mapped the interaction domain in BRD7 that is responsible for p300 binding, and located it in the very C terminus of BRD7, designated BRD7C ( Figure 4c ). As a histone acetyltransferase, CBP/p300 also interacts with acH3K9 ( Figure 4d , lane 2). Interestingly, the p300-acH3K9 association was enhanced by constitutively active type I TGF-β receptor ALK5T202D ( Figure 4d , lane 3), and this interaction is abolished when BRD7 was depleted ( Figure 4d , lanes 4 and 5). Taken together, we believe that BRD7 could facilitate Smad4 transcriptional activity by cooperating with p300. These results indicate that BRD7 is a physiological co-activator in TGF-β signaling through its interactions with both Smads and CBP/ p300.
After having determined the roles of various domains in BRD7, we further analyzed whether deletions of identified domains could affect the function of BRD7 in TGF-β transcriptional responses. As shown in Figure 4e , deletions of any functional domains weakened its ability to potentiate TGF-β-induced S2pcE and PAI-1 reporter gene activation. We also examined the functions of individual domains by rescue experiments. We introduced back deletion mutants into otherwise BRD7-depleted A549 cells, and found that BRDΔ1, BRDΔ2 and BRDΔ5 all failed to fully rescue TGF-β-induced responses (Figure 4f ). These results support the notion that the Smad-binding, p300-binding and bromodomains are critical for BRD7-dependent co-activation in TGF-β signaling.
BRD7 enhances TGF-β-induced cytostatic and tumor suppressive responses As a multifunctional cytokine involved in many important cellular processes, TGF-β controls numerous cellular processes, including cell proliferation, apoptosis and epithelial-mesenchymal transition (EMT). 28 Since we already established the role of BRD7 in Smad-DNA binding and Smad-mediated transcriptional activity, we next sought to examine whether BRD7 could control the strength of TGF-β physiological responses. For this purpose, we first performed bromodeoxyuridine (BrdU) staining in HaCaT cells to dissect the role of BRD7 in TGF-β-induced inhibition on cell proliferation. As shown in Figure 5a , BRD7 knockdown attenuated the phenotype of TGF-β-induced antiproliferation. Consistently, TGF-β-induced G1-S cell cycle arrest was also inhibited in BRD7 knockdown cells, compared with control cells (Figure 5b ). This suggests that BRD7 functions in TGF-β-induced Smad-dependent cell growth inhibition.
As a Smad co-activator in the TGF-β antiproliferative response, it is reasonable to speculate that BRD7 could inhibit tumorigenesis in vivo. To test this, we evaluate the ability of BRD7 to suppress tumor formation. Because BRD7 was reported to function in oncogenic-induced p53-dependent senescence, 19 we attempted to exclude possible involvement of p53 in TGF-β tumor suppressive actions. We stably expressed BRD7 wild-type (WT) and deletion mutants (Δ1, Δ2, Δ5) in H1299 cells. H1299 cells are human non-small cell lung carcinoma with partial deletion of the TP53 gene, resulting in the lack of p53 expression. As shown in Figures 5c-e, when H1299 tumor cells were injected into nude mice, BRD7 WT displayed an apparently suppressive effect on tumor formation, as H1299-BRD7WT cells produced fewer and smaller tumors than H1299-GFP control cells. Meanwhile, three mutants that lack the Smad-binding domain (BRD7Δ1), bromodomain (BRD7Δ2) and p300-binding domain (BRD7Δ5) exhibited weak or no tumor suppressive functions in comparison to WT BRD7. Moreover, we found that the p21 protein level is dramatically increased in tumors expressing BRD7, but not BRD7Δ1 and BRD7Δ2 mutants (Figure 5f ). These results indicate that BRD7 enhances TGF-β signaling in the tumors dependent of its binding to Smad, acetyl group and p300.
BRD7 potentiates TGF-β-mediated EMT responses TGF-β has a paradoxical effect on tumorigenesis. While it inhibits cell proliferation and tumor formation, TGF-β is a potent inducer of EMT, cell motility and cell invasiveness. Thus, we also tested if BRD7 is involved in TGF-β-induced EMT. To this end, we used immortalized mammary epithelial cell line MCF10A, which undergoes EMT in response to TGF-β. 29 To examine the effect of BRD7 on EMT, we established MCF10A cells that stably express HA-BRD7. Interestingly, expression of BRD7 enabled MCF10A cells to produce slightly loose cell-cell adhesion toward an EMT-like morphological change in comparison with MCF10A-GFP cells (Figure 6a ). TGF-β stimulation further profoundly promoted the EMT, while treatment with TGF-β type I receptor kinase inhibitor SB431542 reverted the cells to epithelial phenotype (Figure 6a ). The morphological transition was further confirmed by examination of specific protein markers characteristic of epithelial and mesenchymal cells, for example, E-cadherin, Vimentin and Actin. First, the immunofluorescence experiment found that MCF10A-BRD7 cells exhibited decreased staining of E-cadherin at cell adhesion and increased staining of Vimentin in cells. These cells responded to TGF-β more potently to induce the corresponding changes (Figure 6b ). Second, western blotting and qRT-PCR analyses demonstrated that the decrease in protein and mRNA levels of E-cadherin was more obviously observed in MCF10A-BRD7 cells than control cells (Figures 6c and d) . Likewise, more profound increases in Vimentin protein and Fibronectin mRNA were found in MCF10A-BRD7 (Figures 6d and e ). Last, as a result of Figure 1 . BRD7 interacts with Smad3 and Smad4 under physiological conditions. (a) BRD7 interacts with Smad proteins in vivo. HA-BRD7 and Flag-Smad1/2/3/4 were co-transfected into HEK293T cells. Cells lysates were harvested after 24 h and then immuoprecipitated (IP) with anti-FLAG antibody (α-FLAG). After extensive wash, the immunoprecipitates were then separated on SDS-PAGE and analyzed by western blotting (WB) using appropriate antibodies. (b) BRD7 interacts with Smad proteins in vitro. GST-Smad1/2/3/4 proteins were purified from E. coli strain BL21 (DE3). HA-BRD7 proteins, generated by using in vitro transcription and translation kit, were incubated with GST-Smads or GST only for 3 h at 4°C, and then detected by WB with anti-HA (α-HA) antibody. Inputs of GST fusion proteins were stained by Ponceau S dye on membrane. (c) BRD7 binds to Smad3 under physiological conditions. A549 cells stably expressing BRD7 were harvested and immunoprecipitated with anti-Smad3 antibody (α-Smad3) after 2 h TGF-β treatment. Anti-IgG antibody (α-IgG) was used as a control. Immunoprecipitated proteins and inputs were analyzed as described in (a). (e) BRD7 forms a ternary complex with Smad3 and Smad4. Expression plasmids for FLAG-Smad3, Myc-Smad4, HA-BRD7 and/or HA-ALK5204D were co-transfected into HEK293T cell. Cell lysates were harvested after 24 h and then IP with anti-FLAG (α-FLAG) antibody. After extensive wash, the binding proteins were eluted by incubation with FLAG peptide, followed by second IP with anti-HA (α-HA) antibody. The final immunoprecipitates were then separated on SDS-PAGE and analyzed by WB using appropriate antibodies. (f) Depletion of Smad3 has little effect on the BRD7-Smad4 association. Control or Smad3-targeting siRNA was transfected into A549-BRD7 stable cells and the cells were treated with TGF-β for 2 h. Cell lysates were harvested and IP with anti-HA antibody (α-HA). Anti-IgG (α-IgG) was used as control. The immunoprecipitates were then separated on SDS-PAGE and analyzed by WB using appropriate antibodies. (g) Diagram of Smad3 deletion mutants used in domain-mapping experiments. The start and end amino-acid residues for each fragment are indicated. '+' marks detectable interaction, whereas '-' marks lack of detectable interaction. (h) Smad3 interacts with BRD7 through its MH1 and MH2 domains. FLAG-Smad3 mutants and HA-BRD7 were co-transfected into HEK293T cells. IP-WB was done as described in (a). (i) Diagram of BRD7 deletion mutants. The start and end amino-acid residues for each fragment are indicated. '+' marks detectable interaction, whereas '-' marks lack of detectable interaction. (j) BRD7N (aa 1-129) is essential for Smad3 binding. HEK293T cells were transfected with HA-BRD7 mutants and FLAG-Smad3 plasmids. IP-WB was done as described in (a). (k) BRD7N is sufficient for Smad3 binding in vivo. BRD7N and BRD7WT were co-transfected into HEK293T cells with or without Smad3. IP-WB was done as described in (a, l). BRD7N is sufficient for Smad3 binding in vitro. GST-Smad3 was purified from E. coli strain BL21 (DE3), BRD7 and BRD7N proteins were generated by in vitro transcription and translation kit. GST pulldown was done as described in (b).
EMT, expression of BRD7 conferred MCF10A cells much higher motility than control MCF10A-GFP cells in wound-healing assays, which could also be blocked by SB431542 (Figure 6f ). These results suggest that BRD7 enabled or sensitized cells to undergo EMT.
DISCUSSION
Emergent evidence suggests that BRD7 functions in regulating cell proliferation, oncogene-induced senescence and other cellular processes. [30] [31] [32] BRD7 acts as a tumor suppressor in a number of cancer types. [17] [18] [19] 24, [30] [31] [32] [33] Consistently, its promoter was hypermethylated in tumors. 24 BRD7 has been reported to inhibit cell proliferation and promote cell cycle arrest through various mechanisms. 19, 31 BRD7 can act through the p53 and the PI3K pathways, 20, 26, 34 yet there are conflicting results about the absolute role of these pathways in mediating physiological functions of BRD7. Through the interaction with p53, BRD7 is recruited to the promoters of p53 target genes to mediate p53-dependent oncogenic-induced senescence. On the contrary, BRD7 can confer tumor suppression in tumors lacking p53, 19 suggesting that p53 is not essential in mediating BRD7 tumor-suppressing functions. Moreover, BRD7 binds to p85α subunit of PI3K and sequesters p85 from the catalytic subunit p110, thereby resulting in attenuation of the growth-promoting PI3K signaling. 17 Opposite data have found that BRD7 is able to induce cell cycle inhibitor p21 in cells with p85α and/or p85β deficiency, indicating that PI3K is dispensable for the growth inhibitory function of BRD7. 17 These conflicting data suggest that there are alternative mechanisms underlying the growth inhibitory actions of BRD7. Our current results provide convincing evidence that BRD7 achieve its functions perhaps partly through the TGF-β growth inhibitory pathway. Indeed, BRD7 profoundly promotes TGF-β-induced cell growth inhibition and inhibits tumorigenesis even in the p53 null background. Knockdown of BRD7 dampens the ability of TGF-β in inducing growth inhibition and G1 arrest. Thus, our study assigns a new function to BRD7 in cell growth regulation through the TGF-β pathway.
Our results have found that BRD7 has no effects on receptormediated phosphorylation and activation processes (unpublished observations). Notably, BRD7 interacts with the Smad3/4 complex in a TGF-β-dependent manner. Furthermore, BRD7 mediates a (c) TGF-β enhances BRD7-acH3K9 interaction. HaCaT cells stably expressing HA-BRD7 were treated with 2 ng/ml of TGF-β for 2 h. Cell lysates were harvested and immunoprecipitated with anti-IgG (α-IgG) or anti-HA antibody (α-HA). BRD7-bound acetylated histones were detected with anti-acH3K9 antibody (α-acH3K9). (d) BRD7 promotes Smad4-acH3K9 interaction. FLAG-Smad4 and HA-BRD7 or HA-BRD7Δ2 were co-transfected into HEK293T cells. Constitutively active TGF-β type I receptor HA-ALK5T204D was used to activate TGF-β signaling. IP-western blotting (WB) using indicated antibodies was done as described in Figure 1a . (e) The association between Smad3 and Ac-H3K9 is enhanced by BRD7 and ALK5T202D. FLAG-Smad3 and HA-BRD7 and/or Myc-ALK5T202D were co-transfected into HEK293T cells. Cell lysates were immunoprecipitated with anti-FLAG (α-FLAG). Anti-IgG (α-IgG) were used as control. IP-WB was done using indicated antibodies as described in Figure 1a . (f) BRD7 is essential for Smad4-acH3K9 binding. Control siRNA or siRNA against BRD7 was transfected into HEK293T cells for 24 h; HA-ALK5T204D was introduced to activate TGF-β signaling. IP-WB using indicated antibodies was done as described in Figure 1a .
stronger Smad4-DNA complex formation and induces Smad transactivation activity through its binding with p300 upon TGF-β stimulation. Functional analysis demonstrates that BRD7 strongly potentiates TGF-β-induced transcriptional responses in various cell lines. Our studies highlight BRD7 as a transcriptional co-activator of Smads in TGF-β-induced signaling (Figure 6g ). Interestingly, a direct HEK293T cells were transfected with HA-BRD7 and FLAG-p300. IP-western blotting (WB) was done using the indicated antibodies as described in Figure 1a . (c) BRD7 interacts with p300 through its C terminus. HAtagged BRD7 or its deletion mutants were transfected into HEK293T cells together with FLAG-p300. Domains responsible for p300 binding were examined by IP-WB as described in Figure 1a. (d) BRD7 is essential for the p300-acH3K9 binding. Control siRNA or siRNA against BRD7, HA-ALK5T204D and HA-p300 were transfected into HEK293T cells for 24 h. IP-WB using indicated antibodies was done as described in Figure 1a . (e) Bromodomain, Smad-binding and p300-binding domains are required for TGF-β-induced signaling. BRD7, BRD7 mutants and PAI-1-luc were co-transfected into HaCaT cells. Cell transfection, reporter assays and data analysis were done essentially as described in Figure 2a . (f) Full-length BRD7 rescues TGF-β-induced responses in BRD7-depleted cells. Mouse derived full-length BRD7, BRD7Δ1, BRD7Δ2 or BRD7Δ5 were stably expressed in A549 cells. Control siRNA or siBRD7 were transfected into these cell lines by using RNAiMax. Reporter assays and data analysis were done essentially as described in Figure 2a .
interaction between BRD7 and Smad1, a bone morphogenetic protein (BMP)-specific Smad, has also been observed in our experiments. Similarly, BRD7 can enhance BMP2-induced transcriptional response ( Supplementary Figure 3) , which indicates that BRD7 may also be involved in BMP-regulated cell functions.
BRD7 interacts with Smad3/4 through its N terminus, which also binds to p53 19 . Our attempts to further distinguish the Smad binding and p53 binding have failed, as any destruction on the BRD7N domain results in the failure in Smad4 binding, indicating that the structural integrity of BRD7N is critical for Smad4 binding (unpublished observations). In addition to the Smad binding, BRD7 binds to acetyl-histones. As previously reported, BRD7 is a component of SWI/SNF complexes to regulate transcription. 26, 35 Notably, BRD7 enhances the DNA-binding activity of Smad proteins in both in vitro and in vivo assays (Figures 3a and b) . Considering the fact that the bromodomain of BRD7 directly associates with acetylated histone, 26 we hypothesize that BRD7 may stabilize the Smad-DNA complex through its interaction with acetylated histone. Indeed, TGF-β enhances BRD7-acetyl-histone interaction. Furthermore, the association between Smad3/4 and acetyl-histone is dependent on the presence of BRD7 (Figures 3d  and e ), but not bromodomain-defective mutant BRD7Δ2 (Figure 3d ). In consistence, BRD7 depletion dramatically decreases TGF-β-induced Smad4 association with acetyl-histone. Taken together, BRD7 promotes Smad-chromatin association through its bromodomain.
In the Smad nucleoprotein complex, BRD7 has a dual role in augmenting transcriptional activity. In addition to its bridging role to connect Smad with acetyl histones, it further promotes engagement of p300/CBP, another transcriptional co-activator. It has previously been reported that CBP/p300 cooperates with the Smads complex to facilitate the transcriptional regulation function of Smad proteins. 11, 19 We found that TGF-β enhances the association between p300 and BRD7 as well as that between p300 and acetyl-histone, while this enhancement is absent when BRD7 is depleted in cells. Thus, TGF-β induces the formation of a more stable nucleoprotein complex consisting of Smad4, BRD7, p300/CBP and chromatin (DNA and acetyl-histone).
In summary, our study has elucidated an important function of BRD7 in the TGF-β signaling pathway. As the TGF-β/BMP signaling suppresses tumorigenesis in mouse models. H1299 cells that stably express GFP, BRD7 or a BRD7 mutant were subcutaneously injected into nude mice. Forty-five days after cell implantation, mice were scarified and photographed (c), and tumors were photographed (d) and weighed (e). (f) Expression levels of BRD7 (WT and mutants), Smad4 and p21 protein in tumors were examined by western blotting analysis.
pathways also play important roles in tissue differentiation and embryogenesis, BRD7 may be a pivotal regulator in development. Genetic ablation of the Brd7 gene has resulted in impaired cognitive behavior in mice. 36 Given the involvement of BRD7 in multiple pathways, BRD7 may converge these signaling pathways to function in cell growth control, development and tumorigenesis. Whether the Brd7 knockout phenotype is attributed to the alterations in TGF-β/BMP signaling in development awaits further investigation.
MATERIALS AND METHODS
Plasmids and antibodies
Expression plasmids for FLAG-tagged Smads and mutants, FLAG-ALK5T202D (a constitutively active mutant of rat TGF-β type I receptor with the Thr-to- Asp substitution at the amino-acid residue 202), HA-p300 and reporter plasmids SBE-Luc and PAI-1-Luc were described previously. 37, 38 HA-BRD7 was subcloned into pRK3HA vector. BRD7 deletion mutants and HA-ALK5T204D (a constitutively active mutant of human TGF-β type I receptor with the Thr-to-Asp substitution at the amino-acid residue 204; an equivalent of rat ALK5T202D) were generated by PCR-directed site mutagenesis. Antibodies were obtained as follows: anti-FLAG (F3165), mouse IgG (I5381) and anti-βactin (A5441) from Sigma (St Louis, MO, USA) anti-Myc (sc-40), and anti-Smad4 (sc-7966) antibodies from Santa Cruz (Dallas, TX, USA); anti-HA (3724), anti-p21 (2947), anti-acetylated-H3K9 (9649s), anti-Vimentin (5741) and anti-E-cadherin (3195s) from Cell Signaling Technology (Danvers, MA, USA); peroxidase-conjugated goat anti-rabbit (111-035-045) and rabbit anti-mouse (315-035-048) from Jackson ImmunoResearch (West Grove, PA, USA).
Cell culture and transfection HEK293T, A549 and H1299 cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum, HaCaT cells were maintained in MEM supplemented with 10% fetal bovine serum. HaCaT and A549 cells were transfected with X-tremeGENE (Roche, Basel, Switzerland) and 293 T cells with PEI (Polyscience, Warrington, PA, USA). A549-BRD7 stable cells, HaCaT-BRD7 stable cells, MCF10A-BRD7 stable cells and H1299-BRD7 stable cells were obtained by using lentiviral infection. Briefly, full-length or mutated BRD7 cDNA was subcloned into pWPI-puro vector and transfected into 293 T cells together with packaging plasmid psPAX2 and envelope plasmid pMD2.G. Media containing viruses were collected after 48 h and then used to infect host cells. Stable cells were then selected with 2 μg ml −1 puromycin (Sigma).
Transcriptional reporter assay
HaCaT cells were transfected with reporter plasmids and expression plasmids for BRD7 and/or Smads as indicated in the figures. Twenty-four hours after transfection, cells were treated with TGF-β (2 ng/ml) for 12 h. Cells were then harvested and analyzed with the Dual Luciferase Reporter Assay system (Promega, Madison, WI, USA). 39 All assays were repeated for three times. The values are the average of triplicates ± s.d.
Immunoprecipitation and western blotting analysis
Cells were transfected with expression plasmids for BRD7 and/or Smads as indicated in the figures. Twenty-four hours after transfection, cell lysates were harvested by NEDT lysis buffer (150 mM NaCl, 150 mM Tris-HCl (pH7.5), 2 mM EDTA, 0.5% NP40) and incubated together with protein A Sepharose CL-4B (GE Healthcare, Waukesha, WI, USA) and appropriate antibodies for 4 h at 4°C. After extensive washes, immunoprecipitated proteins were eluted in SDS sample loading buffer, separated by SDS-PAGE, transferred onto polyvinylidene difluoride membranes (Millipore), and detected by western blotting analysis.
GST pull-down assay GST fusion proteins were expressed in E. coli BL21 (DE3) strain and purified by glutathione-Sepharose 4B beads (GE Healthcare) according to manufacturer's instructions. In vitro transcription/translation was performed with the TNT @ quick system (Promega). GST pull-down assays were carried out as described previously. 38 DNA pull-down assay Cells transfected with expression plasmids were lysated in DNAP-lysis buffer (50 mM NaCl, 25 mM Tris-HCl (pH7.4), 0.5% Triton X-100) and then were incubated with 1 μmol biotinylated SBE oligonucleotides (5′-GTACATTGTCAGTCTAGACATACT-3′) in DNAP binding buffer (50 mM KCl, 10 mM Tris-HCl [pH7.4], 5% glycerol) at room temperature for 30 min. DNA-protein complexes were collected by incubating with streptavidin beads (GE Healthcare) for 15 min, and identified by Western blotting after extensive washes.
RNA interference
Small interfering RNAs (siRNAs) targeting human BRD7 were purchased from Dharmacon, (si#1 target sequence: 5′-GUGCCAAGAUUAUCCGUAU-3′; si#2 target sequence: 5′-GUACUAAUGCCAUGAUUUA-3′). siRNA were transfected into A549 or HaCaT cells for 48 h using Lipofectamine RNAiMAX Reagent (Invitrogen).
ChIP assay
ChIP assays were performed using a kit from Upstate Biotechnology and following the manufacturer's instructions. The immunoprecipitated nucleoprotein complexes were eluted by incubation twice for 15 min at 25°C with 200 μl of elution buffer (1% SDS, 100 mM NaHCO 3 ), and crosslinks were reversed at 65°C for 4 h. DNAs were extracted with phenol/chloroform and precipitated with ethanol. The p21 promoter DNA was amplified in a PCR by using forward primer (5′-TGCTGGAACTCGGCCAGGCT-3′) and reverse primer (5′-AGCGCGGCCCTGATATACAAC-3′).
Cell proliferation assay
Cell proliferation was measured by using BrdU ELISA kit (Roche) according to the manufacturer's instructions. Cells were seeded in 96-well culture plates (4000 cells per well) and treated for 4 h with BrdU labeling solution. After fixation and denaturation, cells were detected by anti-BrdU antibody and results were read in a luminometer.
FACS analysis
Cell cycle was measured by using cell cycle staining kit (MultiSciences Biotech, Hangzhou, China) according to the manufacturer's instructions and then analyzed immediately by flow cytometry using FACScan (Becton Dickinson, Franklin Lakes, NJ, USA).
In vivo tumor formation assay
A total of 1 × 10 6 H1299 cells stably expressing GFP (control) or WT or mutated BRD7 were suspended in 100 μl RPMI 1640 cell culture media and then injected subcutaneously into the hind legs of 6-week-old nude mice. Four groups of mice (n = 4) were tested. Mice were killed at 45 days post injection and tumors were excised and measured. ABBREVIATIONS acH3K9, acetyl histone H3 Lys9; BMP, bone morphogenetic protein; BRD7, bromodomain-containing protein 7; EMT, epithelial-mesenchymal transition; GST, glutathione S-transferase; HAT, histone acetyltransferase; P/CAF, p300/CBP-associated factor; qRT-PCR, quantitative real-time PCR; SIP1, Smad-interacting protein 1; TGF, transforming growth factor beta; TGIF, TG-interacting factor; SMIF, Smad4-interacting protein; SXS motif, Ser-X-Ser motif; WT, wild-type.
